• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation, February 15, 2012 - Flucelvax

 

Date/Time of Call:                             February 15, 2012 @ 11 AM
 
CBER Representative:                    
Pete Amin, Reviewer, CBER/OCBQ/DMPQ/MRBII
Marion Michaelis, Team Leader, CBERR/OCBQ/DMPQ/MRBII
Ellen Huang, CSO, CBER/OCBQ/DMPQ/MRBII
 
Organization Representative:         
John Berry, Head of Regulatory Affairs, Novartis Vaccines and Diagnostics, Inc.
Umang Shah, Regulatory Affairs CMC, Novartis Vaccines and Diagnostics, Inc.
 
Organization:                                    Novartis Vaccines and Diagnostics
                                                           
Telephone:                                         ------------(b)(4)-----------------------------
 
Subject:                                              BLA STN 125408/0, Holly Springs
 
STN:                                                   STN 125408/0
                       
 
We contacted Novartis to discuss the Holly Springs, NC facility. Novartis stated that the Holly Springs facility will be doing testing and warehousing. The final product will be shipped to Holly Springs from (b)(4) or Marburg. The firm also stated that they will be submitting a validation report for a new SRID method (parallel line) for the monovalent and --------(b)(4)-------- as an amendment.
 
Novartis also explained to us their future plans for Holly Springs including --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(b)(4)---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.